Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosmanogepix pharmacokinetics in hepatic impairment
NCT05582187Phase 1Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Oct 2022
- Primary completion
- Oct 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fosmanogepix (5 cohorts), sponsored by Basilea Pharmaceutica. Primary endpoints: Maximum Observed Plasma Concentration of manogepix at 240 hours, Area Under the Curve From Time Zero to Last Quantifiable Concentration of manogepix at 240 hours and 4 more. Started Oct 2022; status: completed.
02
Drugs
fosmanogepix
Beyond the preview
Go deeper on NCT05582187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582187.